Skip to content

Hyperglycemia and Mitochondrial Function in The Endothelium of Humans

Hyperglycemia and Mitochondrial Function in The Endothelium of Humans

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02682342
Enrollment
35
Registered
2016-02-15
Start date
2016-03-09
Completion date
2022-11-22
Last updated
2025-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Hyperglycemia

Brief summary

In this study, the investigators will test the hypothesis that acute in vivo exposure to hyperglycemia increases mitochondrial network fragmentation and mitochondrial reactive oxygen species production (ROS) production in human arterial endothelial cells.

Detailed description

Subjects will be recruited according to our inclusion/exclusion criteria. The investigators employ a multifaceted approach to recruitment, including flyers, community newspaper ads, internet ad postings, and direct recruitment from the Internal Medicine Clinics of Froedtert Memorial Lutheran Hospital/Medical College of Wisconsin which saw approximately 50,000 unique outpatient visits over last year. The electronic health record is leveraged to identify potential subjects by HIPAA guidelines and Medical College of Wisconsin policies. Potential subjects will undergo phenotyping that includes a detailed medical history, anthropomorphic measurements, blood pressure and heart rate measurements, and a blood draw for measurements that include fasting lipids, glucose, and glycosylated hemoglobin, creatinine, and liver function tests. Healthy, non-DM subjects who pass the screening as per the inclusion/exclusion criteria in Table 2 will be enrolled in the study protocol. Following an overnight fast (12 hours), subjects will come in the morning to our Adult Translational Research Unit (A-TRU) which is part of the Clinical Translational Research Initiative of Southeast Wisconsin (8UL1TR000055). An antecubital intravenous line will be placed to facilitate blood glucose sampling during the hyperglycemic challenge. An antecubital intravenous catheter will be placed to facilitate obtaining endothelial cells from the vein by J-wire biopsy for of mitochondrial testing. The principal investigator has published experience with the J-wire endothelial cell biopsy technique, and the technique has been extensively validated technique. An initial venous glucose sample will be taken from the antecubital vein and an initial J-wire biopsy of the radial artery endothelium will be performed through the radial arterial line. Subjects will then be asked to drink a standardized 75 g glucose drink created by the A-TRU nutritionist- a standard oral glucose challenge as used clinically. Blood glucose samples will be taken hourly after that until 4 hours post drink ingestion. At one and 4 hours post-ingestion, J-wire endothelial biopsies of the radial artery will be repeated. Four separate J wires will be passed into the radial artery for each measurement time point (0,1, and 4 hours). In non-diabetic subjects, the 75 g oral challenge induces a peak increase in systemic glucose at 1-hour post-administration at which time endothelial dysfunction is concomitantly detectable. Endothelial cells will be obtained via J-wire capture technique. A portion of the endothelial cells isolated from the J-wires will be used to measure mitochondrial network complexity prior hyperglycemic challenge, 1-hour post challenge, and 4 hours post challenge. The investigators will visualize the mitochondrial networks in these cells using our previously reported and validated immunofluorescence method using cytochrome c antibodies to tag the mitochondria. Network fragmentation (high number=greater fragmentation and fission) will be quantified by network fragmentation count calculated with ImageJ (NIH, Bethesda) using a validated protocol.

Interventions

OTHER75 g glucose solution

This is the same as the standard oral glucose challenge dose and route given clinically

Sponsors

Medical College of Wisconsin
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
21 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

1. Adult age 21 to 70 2. No evidence of metabolic syndrome or diabetes, hypertension (BP≥140/90), or high cholesterol (LDL≥160) at the time of screening.

Exclusion criteria

1. History of stroke, peripheral arterial disease, or coronary artery disease (as defined by the presence of at least one coronary stenosis ≥ 40% on angiography or by confirmed history of myocardial infarction by standard criteria). 2. History of bleeding disorders. 3. Evidence of other evident major illness including chronic renal insufficiency (plasma creatinine \> 1.4 for women or 1.5 for men), liver disease (liver enzymes greater than 2.5 x normal), and cancer 4. currently undergoing therapy or had therapy for cancer within 1 year of enrollment. 5. Pregnancy as determined by urinary human chorionic gonadotropin beta test 6. Thienopyridine, anti-thrombin/Xa, or warfarin therapy at time of screening 7. On medication for cholesterol or blood pressure

Design outcomes

Primary

MeasureTime frameDescription
Change in Mitochondrial Network Complexity of Endothelial Cells as Measured by Mitochondrial Network Fragment RatioMeasured at 0,1, and 2 hours after administrationThe investigators visualize the mitochondrial network complexity in these cells using our previously reported and validated immunofluorescence method using cytochrome c antibodies to tag the mitochondria. Network fragmentation (total number of fragments/ total fluorescent pixels\*100) will be quantified by network fragmentation count calculated with ImageJ (NIH, Bethesda) using a validated protocol.

Countries

United States

Participant flow

Recruitment details

Recruitment in southeastern Wisconsin by flyers and electronic advertisements from November 2016 through December 2019

Pre-assignment details

Four subjects were disqualified during screening for cardiovascular risk factors (3 due to elevated total cholesterol and one due to hypertension). One additional subject withdrew consent during screening. One additional subject qualified for the study but never scheduled a study visit. These subjects are not in the 35 subject considered enrolled in the study

Participants by arm

ArmCount
Healthy Subjects
Healthy subjects meeting inclusion criteria will be administered a 75 g glucose solution one time (orally). Subjects will be ages 21-70 years with no evidence of diabetes, hypertension, metabolic syndrome, or high cholesterol at the time of screening. Potential subjects with a history of atherosclerotic disease, chronic renal insufficiency (plasma creatinine \> 1.5 men, \> 1.5 women), liver enzymes \> 2.5x normal, pregnant at the time of screening will be excluded 75 g glucose solution: This is the same as the standard oral glucose challenge dose and route given clinically
35
Total35

Baseline characteristics

CharacteristicHealthy Subjects
Age, Continuous38 years
STANDARD_DEVIATION 18
Body Mass Index26.6 kg/m2
STANDARD_DEVIATION 4.3
Diastolic Blood Pressure72 mmHg
STANDARD_DEVIATION 7
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
33 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Fasting Glucose93 mg/dl
STANDARD_DEVIATION 9
HDL Cholesterol63 mg/dl
STANDARD_DEVIATION 21
Heart Rate70 bpm
STANDARD_DEVIATION 11
Hemoglobin A1C5.4 %
STANDARD_DEVIATION 0.4
LDL Cholesterol106 mg/dl
STANDARD_DEVIATION 26
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
2 Participants
Race (NIH/OMB)
Black or African American
4 Participants
Race (NIH/OMB)
More than one race
2 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
27 Participants
Region of Enrollment
United States
35 participants
Serum Creatinine0.88 mg/dl
STANDARD_DEVIATION 0.18
Sex: Female, Male
Female
14 Participants
Sex: Female, Male
Male
21 Participants
Systolic Blood Pressure118 mmHg
STANDARD_DEVIATION 10
Total Cholesterol183 mg/dl
STANDARD_DEVIATION 35
Triglycerides71 mg/dl
STANDARD_DEVIATION 28
Waist Circumference91 cm
STANDARD_DEVIATION 13

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 35
other
Total, other adverse events
4 / 35
serious
Total, serious adverse events
0 / 35

Outcome results

Primary

Change in Mitochondrial Network Complexity of Endothelial Cells as Measured by Mitochondrial Network Fragment Ratio

The investigators visualize the mitochondrial network complexity in these cells using our previously reported and validated immunofluorescence method using cytochrome c antibodies to tag the mitochondria. Network fragmentation (total number of fragments/ total fluorescent pixels\*100) will be quantified by network fragmentation count calculated with ImageJ (NIH, Bethesda) using a validated protocol.

Time frame: Measured at 0,1, and 2 hours after administration

Population: The samples quality when we went back to look at the cells was too poor to obtain valid and reproducible measurements so the outcome was not used.

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026